Michieli P, Li W, Lorenzi M V, Miki T, Zakut R, Givol D, Pierce J H
Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892, USA.
Oncogene. 1996 Feb 15;12(4):775-84.
The p53-regulated p21Waf1 protein is a universal inhibitor of cyclin-dependent kinases (CDKs). To study the potential tumor-suppressive properties of CDK inhibitors, the ability of p21Waf1 to interfere with oncogene-mediated cellular transformation was analysed in the NIH3T3 cell system. Cotransfection of waf1 together with activated ras or several other oncogenes into NIH3T3 cells potently inhibited the formation of transformed foci in a dose-dependent manner. Expression of the CDK-binding N-terminal half of p21Waf1 (N-p21Waf1) was necessary and sufficient to inhibit Ras-induced focus formation. In contrast, expression of the C-terminal domain (C-p21Waf1) had no effect on Ras-induced focus formation. Immunofluorescence analysis revealed that ectopically expressed p21Waf1 and C-p21Waf1 were localized in the nucleus, while N-p21Waf1 was found in the cytoplasm, with the tendency to accumulate around the nuclear membrane. Surprisingly, stable NIH3T3 transfectants expressing ectopic p21Waf1 grew at the same rate and displayed similar cell cycle distribution as NIH3T3 cells transfected with the same vector containing no insert. However, ectopic p21Waf1 expression did inhibit Ras-mediated anchorage-independent colony formation, indicating that p21Waf1 can selectively interfere with oncogene-mediated transformation without affecting NIH3T3 cell growth, at least at the levels of p21Waf1 expression achieved in these experiments. Transient transfection of waf1 into NIH3T3 cells inhibited Ras-induced transcription from a E2F-responsive element but not from a serum-responsive element, indicating that p21Waf1 acts downstream of early transcriptional events induced by Ras but upstream of E2F-controlled gene transcription. These results provide evidence that p21Waf1 potently suppresses oncogene-mediated cellular transformation of NIH3T3 cells and that it may do so by inhibiting E2F-driven transcription of S phase genes.
p53调控的p21Waf1蛋白是细胞周期蛋白依赖性激酶(CDK)的通用抑制剂。为了研究CDK抑制剂的潜在肿瘤抑制特性,在NIH3T3细胞系统中分析了p21Waf1干扰癌基因介导的细胞转化的能力。将waf1与活化的ras或其他几种癌基因共转染到NIH3T3细胞中,以剂量依赖性方式有效抑制转化灶的形成。p21Waf1的CDK结合N端半段(N-p21Waf1)的表达对于抑制Ras诱导的灶形成是必要且充分的。相反,C端结构域(C-p21Waf1)的表达对Ras诱导的灶形成没有影响。免疫荧光分析显示,异位表达的p21Waf1和C-p21Waf1定位于细胞核,而N-p21Waf1位于细胞质中,有在核膜周围积累的趋势。令人惊讶的是,表达异位p21Waf1的稳定NIH3T3转染细胞与用不含插入片段的相同载体转染的NIH3T3细胞以相同的速率生长,并显示出相似的细胞周期分布。然而,异位p21Waf1表达确实抑制了Ras介导的非锚定依赖性集落形成,表明p21Waf1可以选择性地干扰癌基因介导的转化,而不影响NIH3T3细胞生长,至少在这些实验中达到的p21Waf1表达水平是如此。将waf1瞬时转染到NIH3T3细胞中可抑制Ras诱导的来自E2F反应元件的转录,但不抑制来自血清反应元件的转录,表明p21Waf1作用于Ras诱导的早期转录事件的下游,但在E2F控制的基因转录的上游。这些结果提供了证据,证明p21Waf1能有效抑制NIH3T3细胞的癌基因介导的细胞转化,并且它可能通过抑制S期基因的E2F驱动转录来做到这一点。